UnitedHealth Group (UNH) Form 4: This filing reports a non-derivative acquisition by Thomas E. Roos, Chief Accounting Officer, via an authorized filing on behalf of the reporting person. On 09/23/2025 the report shows an acquisition of 22.357 units recorded as dividend equivalents on outstanding restricted stock units, with a reported price of $0 because these are dividend-equivalent payments tied to RSUs and subject to the same vesting and forfeiture terms as the underlying awards. Following the transaction, the reporting person beneficially owned 29,593.519 shares, which includes shares acquired through UnitedHealth’s Employee Stock Purchase Plan. The filing was signed by an attorney-in-fact on 09/25/2025.
Charles D. Baker, a director of UnitedHealth Group Inc. (UNH), filed a Form 4 reporting changes in his beneficial ownership. The filing shows a transaction dated 09/11/2025 reporting 27 shares of Common Stock with transaction code S at a price of $356.05. The Form reports that following the reported transaction the reporting person had 1,248 shares of Common Stock beneficially owned indirectly (by trust). The form also explains that on 08/01/2025 the reporting person acquired indirect beneficial ownership of 27 UNH shares by inheritance, an acquisition the filer states was exempt from reporting under Rules 16a-3 and 16b-5.
UnitedHealth Group (UNH) filer submitted a Form 144 reporting a proposed sale of company common stock. The notice shows 27 shares intended for sale on the NYSE through J.P. Morgan Securities LLC with an aggregate market value of $9,363.06 and an approximate sale date of 09/11/2025. The securities were acquired by transfer on 08/01/2025 from the "Barbara L S Schadt Terminating Trust UAD 12-16-2015" and payment/consideration is listed as N/A. The form indicates no securities sold in the prior three months and contains standard signature and representation language. Some filer identifiers and contact details are not provided in the content.
UnitedHealth Group reaffirmed its adjusted 2025 earnings-per-share outlook and said that the August 2025 acquisition of Amedisys is incorporated into that outlook, noting the acquisition is expected to be dilutive to adjusted EPS because of financing costs and integration investments. The company also discussed preliminary CMS Medicare Advantage star ratings for Star Year 2026/Payment Year 2027 and estimated that about 78% of its membership will be in plans rated 4 stars or higher, which the company says is consistent with expectations and historical performance. The report reiterates customary forward-looking statement cautions and lists factors that could cause actual results to differ materially.
UnitedHealth Group, Inc. filed a Current Report on Form 8-K noting that the document contains forward-looking statements about its financial prospects, operations and risks. The filing lists common examples of forward-looking language and explains that actual results may differ materially due to factors such as medical cost trends, regulatory or legal actions, cybersecurity incidents, changes in government programs, quality scores affecting revenue, contract or market risks, and other operational or financial risks. The company cautions investors not to place undue reliance on these statements and says it will not update them except as required by law.
Wayne S. DeVeydt, Chief Financial Officer of UnitedHealth Group (UNH), reported equity awards on 09/02/2025. He was granted 10,525 restricted stock units and 42,551 non-qualified stock options tied to common stock. The RSUs and options were reported as acquired at $0 on the filing; the options carry an exercise price of $308.8. Both the RSUs and the options vest 25% annually on September 2 in 2026, 2027, 2028 and 2029. Following the transactions, DeVeydt beneficially owns 10,525 shares from the RSUs and the options represent the right to purchase 42,551 shares. The report is a routine Section 16 disclosure of insider compensation-related equity grants.
UnitedHealth Group’s Chief Financial Officer Wayne S. DeVeydt filed an initial ownership report stating he beneficially owns no UnitedHealth Group common stock. The Form 3 shows zero shares of common stock held directly and no derivative securities such as options or warrants as of the event date of September 2, 2025. The filing confirms his role as an officer, specifically Chief Financial Officer, and indicates that all reported ownership is direct, with no indirect holdings listed.
UnitedHealth Group Incorporated reported board governance changes focused on oversight of risk and responsibility. The board created a new Public Responsibility Committee to monitor financial, regulatory, and reputational risks, including underwriting and forecasting, regulatory relationships, reputational matters, and mergers and acquisitions. Michele Hooper will chair this committee, with Charles Baker, Timothy Flynn, and Paul Garcia as members.
The company also named F. William McNabb as lead independent director, succeeding Michele Hooper, who remains on the board. In addition, UnitedHealth Group refreshed leadership and membership across its Audit and Finance, Compensation and Human Resources, Governance, and Health and Clinical Practice Policies Committees, assigning specific directors as chairs and members to each.
UnitedHealth Group Incorporated filed an S-8 registration related to employee benefit plans that incorporates prior SEC reports and exhibits by reference and lists plan documents, charter and bylaw excerpts, legal opinions, auditor consent, and a filing fee table. The filing describes conversion of certain Amedisys RSU awards into Company restricted stock units using an equity award exchange ratio and references the Company’s fiscal year-end disclosure.
UnitedHealth Group reported second-quarter 2025 consolidated revenue of $111.6 billion, up 13% from $98.9 billion a year earlier, driven by premium growth (+14% to $87.9 billion), Optum Rx volume growth and pricing trends. Despite higher revenue, earnings from operations fell to $5.15 billion (down 35%) and net earnings were $3.57 billion (diluted EPS $3.74), reflecting elevated medical costs and Medicare Advantage funding pressures.
Medical costs rose 20% to $78.6 billion for the quarter, pushing the medical care ratio to 89.4% from 85.1%. Year-to-date results show net earnings of $10.05 billion and diluted EPS of $10.61, strong cash from operations of $12.6 billion for six months, available liquidity of about $77.3 billion in cash and investments, a June dividend increase to an $8.84 annual rate, $3.0 billion of senior notes issued in June, and approximately $4 billion of anticipated acquisition capital committed (subject to approvals).